Viewing nowPregabalin Capsule 25 mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
SaeHan Pharmaceutical Co., Ltd.

MFDS item code 201902603 · Approved 2019.04.25 · Insurance code 651300990
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in patients with epilepsy, effective regardless of the presence of secondary generalized symptoms. Additionally, it assists in alleviating symptoms in fibromyalgia patients. In other words, this drug is used to treat neuropathic pain, specific types of epilepsy, and chronic pain syndromes.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Because this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration.’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys in unchanged form. Because clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (ml/min)* *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosing based on renal function ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as indicated in the dosing regimen. b: Supplemental dose refers to a dose administered once in addition. 6. Patients with hepatic impairment No dose adjustment is needed in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behavior, so close observation for mood changes or unusual behavior is necessary during treatment. Patients with hypersensitivity to this medication should not take it. Diabetic patients may experience difficulties in blood sugar control due to weight gain, thus adjustments in diabetes medication may be necessary. If allergic reactions such as angioedema occur, the medication should be discontinued immediately. Elderly patients are at higher risk of accidents due to dizziness or drowsiness, thus caution is required. Blurred vision or changes in eyesight may occur, which can improve after discontinuation of the medication. Caution is recommended during the discontinuation of other antiepileptic medications. Discontinuing the medication suddenly may lead to withdrawal symptoms such as insomnia, headache, and anxiety, and should be discussed with a physician. Patients with a history of substance abuse should take this medication with caution due to a higher risk of misuse. Patients with impaired kidney function may require dosage adjustment. Patients with severe heart disease need to be cautious when using this medication. When taken with central nervous system depressants (e.g., opioids), there is a risk of respiratory depression that should be watched closely. In early pregnancy, there is a risk of fetal malformation, so it is advisable for pregnant women to avoid taking this medication, and sexually active women should use effective contraception. Dizziness or drowsiness may occur during treatment, so driving or operating hazardous machinery should be avoided. Serious skin reactions, such as Stevens-Johnson syndrome, have been reported rarely; if symptoms of skin abnormality occur, discontinue use immediately and consult with healthcare providers. This medication is primarily excreted in urine, and the possibility of interaction with other drugs is low, but taking it with alcohol or central nervous system depressants may increase drowsiness or respiratory depression. Breastfeeding women should be advised to discontinue breastfeeding or the medication, as it may be passed into breast milk. In case of overdose, symptoms such as drowsiness, confusion, and depression may occur; immediate medical attention is required, and treatments such as dialysis may be necessary. Keep out of reach of children, and do not transfer to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent contact with air or moisture, and the safe storage temperature is between 15 to 30 degrees Celsius. Proper storage helps maintain the drug's effectiveness and prevents degradation.
A hard capsule with a light yellow upper part and a white lower part, containing white or grayish-white crystalline powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Hard capsule · Prescription medication
SaeHan Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.